Show simple item record

dc.contributor.authorSeferoglu, Meral
dc.contributor.authorTURAN, ÖMER FARUK
dc.contributor.authorSİVA, Aksel
dc.contributor.authorEthemoglu, Ozlem
dc.date.accessioned2021-12-10T10:06:29Z
dc.date.available2021-12-10T10:06:29Z
dc.identifier.citationSeferoglu M., Ethemoglu O., TURAN Ö. F. , SİVA A., "MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine", NEUROLOGICAL SCIENCES, 2021
dc.identifier.issn1590-1874
dc.identifier.otherav_2971bccd-3c80-4bae-873b-5a954d5b478d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169208
dc.identifier.urihttps://doi.org/10.1007/s10072-021-05409-6
dc.description.abstractBackground The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs' immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system. Methods We report two asymptomatic cases of COVID-19 in patients with relapsing-remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response. Results Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2. Conclusion These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.
dc.language.isoeng
dc.subjectCognitive Neuroscience
dc.subjectKLİNİK NEUROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectNEUROSCIENCES
dc.subjectSinirbilim ve Davranış
dc.subjectTıp
dc.subjectHuman-Computer Interaction
dc.subjectNeurology (clinical)
dc.subjectPhysical Sciences
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectNeurology
dc.subjectDevelopmental Neuroscience
dc.subjectCellular and Molecular Neuroscience
dc.subjectGeneral Neuroscience
dc.subjectNeuroscience (miscellaneous)
dc.subjectSensory Systems
dc.titleMS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
dc.typeMakale
dc.relation.journalNEUROLOGICAL SCIENCES
dc.contributor.departmentUniversity of Health Sciences Turkey , ,
dc.contributor.firstauthorID2692210


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record